Announcements Trials
Browse Landscape

Phase

Phase 2 150Phase 1 36Phase 1/2 34Phase 3 10Phase NA 7Phase 2/3 3Phase EARLY_PHASE1 2Phase 4 2

Status

Withdrawn 1Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Lymphoma, Follicular 1Lymphedema 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Tacrolimus × Clear all
NCT06306274 2024-12-02

Topical Tacrolimus for Breast Cancer-related Lymphedema

Odense University Hospital

Phase 2/3 Enrolling by invitation
80 enrolled

Lymphedema

NCT00096460 2023-01-05

BMT CTN 0202

Medical College of Wisconsin

Phase 2/3 Terminated
30 enrolled 5 charts
Lymphoid

Lymphoma, Follicular

NCT00922129 2014-01-14

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡